The miR-185/PAK6 axis predicts therapy response and regulates survival of drug-resistant leukemic stem cells in CML
Open Access
- 30 July 2020
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 136 (5), 596-609
- https://doi.org/10.1182/blood.2019003636
Abstract
Overcoming drug resistance and targeting cancer stem cells remain challenges for curative cancer treatment. To investigate the role of microRNAs (miRNAs) in regulating drug resistance and leukemic stem cell (LSC) fate, we performed global transcriptome profiling in treatment-naive chronic myeloid leukemia (CML) stem/progenitor cells and identified that miR-185 levels anticipate their response to ABL tyrosine kinase inhibitors (TKIs). miR-185 functions as a tumor suppressor: its restored expression impaired survival of drug-resistant cells, sensitized them to TKIs in vitro, and markedly eliminated long-term repopulating LSCs and infiltrating blast cells, conferring a survival advantage in preclinical xenotransplantation models. Integrative analysis with mRNA profiles uncovered PAK6 as a crucial target of miR-185, and pharmacological inhibition of PAK6 perturbed the RAS/MAPK pathway and mitochondrial activity, sensitizing therapy-resistant cells to TKIs. Thus, miR-185 presents as a potential predictive biomarker, and dual targeting of miR-185-mediated PAK6 activity and BCR-ABL1 may provide a valuable strategy for overcoming drug resistance in patients.This publication has 62 references indexed in Scilit:
- Targeting Primitive Chronic Myeloid Leukemia Cells by Effective Inhibition of a New AHI-1–BCR-ABL–JAK2 ComplexJNCI Journal of the National Cancer Institute, 2013
- High-throughput microfluidic single-cell RT-qPCRProceedings of the National Academy of Sciences of the United States of America, 2011
- MicroRNAs 130a/b are regulated by BCR-ABL and downregulate expression of CCN3 in CMLJournal of Cell Communication and Signaling, 2011
- Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growthProceedings of the National Academy of Sciences of the United States of America, 2010
- miR-328 Functions as an RNA Decoy to Modulate hnRNP E2 Regulation of mRNA Translation in Leukemic BlastsCell, 2010
- Causes and consequences of microRNA dysregulation in cancerNature Reviews Genetics, 2009
- Genetic and Epigenetic Silencing of MicroRNA-203 Enhances ABL1 and BCR-ABL1 Oncogene ExpressionCancer Cell, 2008
- Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid LeukemiaThe New England Journal of Medicine, 2006
- Oncomirs — microRNAs with a role in cancerNature Reviews Cancer, 2006
- MicroRNAs Modulate Hematopoietic Lineage DifferentiationScience, 2004